• Oncolytics Biotech reported accelerating enrollment in its randomized REO 033 study in second-line RAS-mutant, MSS metastatic colorectal cancer.
• Interim Part A clinical results will be presented in the future, with an update targeted for year-end 2026.
• Trial aims to show whether adding pelareorep improves patient outcomes versus standard treatment in a controlled, head-to-head setting.
• FDA alignment outlined a potential accelerated-approval route tied to tumor response, with confirmatory approval tied to longer-term disease control.
• Earlier REO 022 findings have already been presented; REO 033 is designed to validate those signals in a randomized study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280930PRIMZONEFULLFEED9834662) on September 28, 2026, and is solely responsible for the information contained therein.